Novo Nordisk’s Semaglutide Study: A Closer Look at Real-World Effectiveness

Novo Nordisk ((NVO)) announced an update on their ongoing clinical study.

Study Overview: Novo Nordisk is conducting a multicentre, prospective, single-arm, non-interventional regulatory post-marketing surveillance (rPMS) study titled A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea. The study aims to assess the safety and effectiveness of semaglutide, a medication used for weight management, in real-world clinical settings in Korea.

Intervention/Treatment: The study involves the use of semaglutide, a commercially available medication prescribed for weight management in individuals with obesity and overweight. Participants will receive semaglutide as part of their routine clinical care, as determined by their treating physician.

Study Design: This observational study follows a case-only model with a prospective time perspective. It is non-interventional, meaning that semaglutide is administered as per standard clinical practice without additional experimental procedures. The primary focus is on monitoring safety and effectiveness in a real-world context.

Study Timeline: The study began on June 4, 2025, and is currently enrolling participants by invitation. It is expected to last approximately four years, with participants involved for about 26 weeks. The last update was also submitted on June 4, 2025, marking the study’s initiation.

Market Implications: This study could significantly impact Novo Nordisk’s stock performance by providing further evidence of semaglutide’s effectiveness and safety, potentially boosting investor confidence. As the obesity treatment market grows, positive outcomes could enhance Novo Nordisk’s competitive position against other pharmaceutical companies targeting similar conditions.

The study is ongoing, with further details available on the ClinicalTrials portal.